Analyst Price Target is $7.00
▲ +43.15% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Novan in the last 3 months. The average price target is $7.00, with a high forecast of $16.00 and a low forecast of $2.00. The average price target represents a 43.15% upside from the last price of $4.89.
Current Consensus is
The current consensus among 4 polled investment analysts is to buy stock in Novan. This rating has held steady since March 2020, when it changed from a Hold consensus rating.
Novan, Inc. is a biotechnology company, which engages in leveraging nitric oxide's natural antiviral and immunomodulatory mechanisms of action to treat dermatological and oncovirus-mediated diseases. Its products pipeline include SB204, SB206, SB208, and SB414. The company was founded by Mark Schoenfisch and Nathan Stasko in 2006 and is headquartered in Morrisville, NC.